Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...

Washington, D.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Today, the New Civil Liberties Alliance filed an amicus curiae brief in Moats v. National Credit Union Administration Board urging the U.S. Court of Appeals for the Fifth Circuit to reverse an order depriving former Texas credit union CEO Jeffrey Moats of a jury trial. The National Credit Union Administration (NCUA) prosecuted and punished Mr. Moats for alleged misconduct in its in-house tribunal overseen by an Administrative Law Judge (ALJ) it appointed. ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

For the quarter ended September 2024, Amicus Therapeutics (FOLD) reported revenue of $141.52 million, up 36.7% over the same period last year. EPS came in at $0.10, compared to -$0.07 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $133.91 million, representing a surprise of +5.68%. The company delivered an EPS surprise of +25.00%, with the consensus EPS estimate being $0.08.While investors scrutinize revenue and earnings changes year-over-year and how they compare w ...

Exhibit 99.1 Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year GalafoldQ3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti+ Opfolda Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER Reducing non-GAAP Operating Expense Guidance to $340M to $350M Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, NJ, November 6, 2024 – Amicus Therapeutics (Nas ...

Amicus Therapeutics (FOLD) closed the last trading session at $11.47, gaining 8.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17.33 indicates a 51.1% upside potential.The average comprises 12 short-term price targets ranging from a low of $13 to a high of $20, with a standard deviation of $2.39. While the lowest estimate indicates an increase of 13.3% from the current price l ...

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ETJefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMT A live audio webcast of each presentation can also be accessed via the investors section of ...

PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a perso ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Insights - Amicus Therapeutics (FOLD) has signed a licensing agreement with Teva Pharmaceuticals (TEVA), resolving a patent lawsuit related to its drug Galafold, leading to a 14% increase in FOLD's stock price [1][2]. Group 1: Licensing Agreement and Litigation - The agreement allows Teva to sell a generic version of Galafold in the U.S. starting January 30, 2037, pending FDA approval [2]. - The settlement ends all ongoing litigation between Amicus and Teva regarding Galafold patents, but litigation against Aurobindo Pharma continues [2]. Group 2: Galafold Performance - Galafold, Amicus' lead drug, generated $210.2 million in sales in the first half of 2024, reflecting a 17% year-over-year increase at constant currency [5]. - Amicus has raised its revenue guidance for Galafold for 2024 to a growth range of 14-18%, up from the previous 13-17% [5]. - The drug is protected by a strong intellectual property portfolio in the U.S. until 2038, with potential for label expansion and approvals in new markets [5]. Group 3: Additional Drug Portfolio - Amicus has a second FDA-approved drug, Pombiliti + Opfolda, for treating late-onset Pompe disease, which was approved in September 2023 [6]. - The approval of Pombiliti + Opfolda provides significant commercial opportunities and alleviates revenue pressure on Galafold [6]. Group 4: Stock Performance and Rankings - Year-to-date, FOLD shares have decreased by 15.6%, while the industry has seen a decline of 1.3% [4]. - Amicus currently holds a Zacks Rank 1 (Strong Buy), indicating positive market sentiment [7].